FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Jozsef Varga

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Procedures

Physiology

Cell Divisions

Disorders

Prostatic Neoplasms

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Anton Stangelberger; Jozsef Varga; Marta Zarandi; Benjamin Baker; Ferenc Rick; Andrew V Schally; Gabor Halmos
Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
Anna Klukovits; Andrea Papadia; Andrew V Schally; Luca Szalontay; Jozsef Varga; Irving Vidaurre; Marta Zarandi; Norman Block; Gabor Halmos
Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Andrea Papadia; Ferenc Rick; Andrew V Schally; S Seitz; Luca Szalontay; A Treszl; Jozsef Varga; Marta Zarandi; S Bellyei; Stefan Buchholz; Gabor Halmos; Joseph Lucci
Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Jozsef Varga (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2012: Anton Stangelberger; Jozsef Varga; Marta Zarandi; Benjamin Baker; Ferenc Rick; Andrew V Schally; Gabor Halmos
Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
The Prostate 2012;72(5):555-65.
2012: Anna Klukovits; Andrea Papadia; Andrew V Schally; Luca Szalontay; Jozsef Varga; Irving Vidaurre; Marta Zarandi; Norman Block; Gabor Halmos
Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
Cancer 2012;118(3):670-80.
2011: Andrea Papadia; Ferenc Rick; Andrew V Schally; S Seitz; Luca Szalontay; A Treszl; Jozsef Varga; Marta Zarandi; S Bellyei; Stefan Buchholz; Gabor Halmos; Joseph Lucci
Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2011;43(11):816-20.
2010: Hsien-Ming Wu; Andrew V Schally; Jung-Chien Cheng; Marta Zarandi; Jozsef Varga; Peter C K Leung
Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21.
Cancer letters 2010;298(1):16-25.
2010: Eva Pozsgai; Andrew V Schally; Marta Zarandi; Jozsef Varga; Irving Vidaurre; Szabolcs Bellyei
The effect of GHRH antagonists on human glioblastomas and their mechanism of action.
International journal of cancer. Journal international du cancer 2010;127(10):2313-22.
2010: Magdolna Kovács; Andrew V Schally; Florian Hohla; Ferenc Rick; Eva Pozsgai; Luca Szalontay; Jozsef Varga; Márta Zarándi
A correlation of endocrine and anticancer effects of some antagonists of GHRH.
Peptides 2010;31(10):1839-46.
2010: Szabolcs Bellyei; Andrew V Schally; Marta Zarandi; Jozsef Varga; Irving Vidaurre; Eva Pozsgai
GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro.
Cancer letters 2010;293(1):31-40.
2010: Rosemeire M Kanashiro-Takeuchi; Konstantinos Tziomalos; Lauro M Takeuchi; Adriana V Treuer; guillaume lamirault; Raul Dulce; Michael Hurtado; Yun Song; Norman Block; Ferenc Rick; Anna Klukovits; Qinghua Hu; Jozsef Varga; Andrew V Schally; Ivonne Schulman
Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(6):2604-9.
2010: Nektarios Barabutis; Agnieszka Siejka; Andrew V Schally; Norman Block; Renzhi Cai; Jozsef Varga
Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor.
Journal of molecular endocrinology 2010;44(2):127-34.
2010: Jian Guo; Andrew V Schally; Marta Zarandi; Jozsef Varga; Peter C K Leung
Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway.
Reproductive biology and endocrinology : RB&E 2010;8():54.
2009: Florian Hohla; Stefan Buchholz; Andrew V Schally; Stefan Seitz; Ferenc Rick; Luca Szalontay; Jozsef Varga; Marta Zarandi; Gabor Halmos; Irving Vidaurre; AWTAR KRISHAN; Metin Kurtoglu; Sudhir Chandna; Elmar Aigner; Christian Datz
GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells.
Cell cycle (Georgetown, Tex.) 2009;8(19):3149-56.
2009: Elena Theophanous; Constantina D Petraki; Andreas Scorilas; Vassilios Komborozos; George Veloudis; Jozsef Varga; Marta Zarandi; Andrew V Schally; Michael Koutsilieris
The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer.
Molecular medicine (Cambridge, Mass.) 2009;15(7-8):242-7.
2009: Ana Valdehita; Ana M Bajo; Andrew V Schally; Jozsef Varga; María J Carmena; Juan C Prieto
Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
Molecular and cellular endocrinology 2009;302(1):41-8.
2008: Felipe F Casanueva; Jesus P Camiña; Marcos C Carreira; Yolanda Pazos; Jozsef Varga; Andrew V Schally
Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(51):20452-7.
2008: Elmar Heinrich; Andrew V Schally; Stefan Buchholz; Ferenc Rick; Gabor Halmos; Melinda Mile; Kate Groot; Florian Hohla; Marta Zarandi; Jozsef Varga
Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
The Prostate 2008;68(16):1763-72.
2008: Stephan Seitz; Florian Hohla; Andrew V Schally; Angelika Moder; Jörg Engel; Felicitas Horn; Jozsef Varga; Marta Zarandi; Olaf Ortmann; Frank Köster; Stefan Buchholz
Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist.
Oncology reports 2008;20(5):1289-94.
2008: Florian Hohla; Angelika Moder; Ursula Mayrhauser; Cornelia Hauser-Kronberger; Andrew V Schally; Jozsef Varga; Marta Zarandi; Stefan Buchholz; Rudolf Huber; Elmar Aigner; Markus Ritter; Christian Datz
Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon.
International journal of oncology 2008;33(1):137-43.
2008: Magdolna Kovács; Andrew V Schally; Jozsef Varga; Márta Zarándi
Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists.
Current medicinal chemistry 2008;15(4):314-21.
2008: Andrew V Schally; Jozsef Varga; Jörg Engel
Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
Nature clinical practice. Endocrinology & metabolism 2008;4(1):33-43.
2007: Sandra Sotomayor; María J Carmena; Andrew V Schally; Jozsef Varga; Manuel Sánchez-Chapado; Juan Prieto; Ana M Bajo
Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
International journal of oncology 2007;31(5):1223-30.
2007: Anton Stangelberger; Andrew V Schally; Marta Zarandi; Elmar Heinrich; Kate Groot; Alexandre Havt; Celia A Kanashiro; Jozsef Varga; Gabor Halmos
The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
The Prostate 2007;67(12):1339-53.
2007: Celia A Kanashiro; Andrew V Schally; Marta Zarandi; Brian D Hammann; Jozsef Varga
Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.
International journal of oncology 2007;30(4):1019-28.
2007: Stefan Buchholz; Andrew V Schally; Jörg Engel; Florian Hohla; Elmar Heinrich; Frank Koester; Jozsef Varga; Gabor Halmos
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(6):1943-6.
2006: Florian Hohla; Andrew V Schally; Karoly Szepeshazi; Jozsef Varga; Stefan Buchholz; Frank Köster; Elmar Heinrich; Gabor Halmos; Ferenc Rick; Chandrika Kannadka; Christian Datz; Celia A Kanashiro
Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(39):14513-8.
2006: Gabor Halmos; Andrew V Schally; Andrea L F Bernardino; Jozsef Varga
Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas.
International journal of oncology 2006;29(2):463-9.
2006: Marta Zarandi; Jozsef Varga; Andrew V Schally; Judit E Horvath; Gabor L Toller; Magdolna Kovacs; Markus Letsch; Kate Groot; Patricia Armatis; Gabor Halmos
Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(12):4610-5.
2006: Andrew V Schally; Jozsef Varga
Antagonists of growth hormone-releasing hormone in oncology.
Combinatorial chemistry & high throughput screening 2006;9(3):163-70.
2005: Alexandre Havt; Andrew V Schally; Gabor Halmos; Jozsef Varga; Gabor L Toller; Judit E Horvath; Karoly Szepeshazi; Frank Köster; Kevin Kovitz; Kate Groot; Marta Zarandi; Celia A Kanashiro
The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(48):17424-9.
2005: Anton Stangelberger; Andrew V Schally; Jozsef Varga; Marta Zarandi; Renzhi Cai; Ben Baker; Brian D Hammann; Patricia Armatis; Celia A Kanashiro
Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling.
European journal of cancer (Oxford, England : 1990) 2005;41(17):2735-44.
2005: Laura B Jaeger; William A Banks; Jozsef Varga; Andrew V Schally
Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(35):12495-500.
2005: Celia A Kanashiro; Andrew V Schally; Jozsef Varga; Brian D Hammann; Gabor Halmos; Marta Zarandi
Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.
Cancer letters 2005;226(2):123-31.
2005: Anton Stangelberger; Andrew V Schally; Jozsef Varga; Brian D Hammann; Kate Groot; Gabor Halmos; Renzhi Cai; Marta Zarandi
Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
The Prostate 2005;64(3):303-15.
2005: Gunhild Keller; Andrew V Schally; Kate Groot; Gabor L Toller; Alexandre Havt; Frank Köster; Patricia Armatis; Gabor Halmos; Marta Zarandi; Jozsef Varga; Jörg Engel
Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(30):10628-33.
2005: Beatriz Collado; María J Carmena; Manuel Sánchez-Chapado; Antonio Ruíz-Villaespesa; Ana M Bajo; Ana B Fernández-Martínez; Jozsef Varga; Andrew V Schally; Juan Prieto
Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
International journal of oncology 2005;26(6):1629-35.
2005: Jörg Engel; Gunhild Keller; Andrew V Schally; Gabor L Toller; Kate Groot; Alexandre Havt; Patricia Armatis; Marta Zarandi; Jozsef Varga; Gabor Halmos
Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
The Journal of clinical endocrinology and metabolism 2005;90(6):3614-21.
2005: Zoltan Rekasi; Tamas Czompoly; Andrew V Schally; Ferenc Boldizsar; Jozsef Varga; Marta Zarandi; Timea Berki; Reka A Horvath; Peter Nemeth
Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(9):3435-40.
2005: Anton Stangelberger; Andrew V Schally; Jozsef Varga; Marta Zarandi; Karoly Szepeshazi; Patricia Armatis; Gabor Halmos
Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):49-57.
2004: Celia A Kanashiro; Andrew V Schally; Marta Zarandi; Brian D Hammann; Jozsef Varga
Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling.
International journal of cancer. Journal international du cancer 2004;112(4):570-6.
2004: Gabor L Toller; Judit E Horvath; Andrew V Schally; Gabor Halmos; Jozsef Varga; Kate Groot; David Chism; Marta Zarandi
Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(42):15160-5.
2004: Ioulia Chatzistamou; Andrew V Schally; Hippokratis Kiaris; Ekaterini Politi; Jozsef Varga; George Kanellis; Anastasios Kalofoutis; Agathi Pafiti; Helen Koutselini
Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers.
European journal of endocrinology / European Federation of Endocrine Societies 2004;151(3):391-6.
2004: Jozsef Varga; Andrew V Schally; Judit E Horvath; Magdolna Kovacs; Gabor Halmos; Kate Groot; Gabor L Toller; Zoltan Rekasi; Marta Zarandi
Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(6):1708-13.
2004: Markus Letsch; Andrew V Schally; Anton Stangelberger; Kate Groot; Jozsef Varga
Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.
European journal of cancer (Oxford, England : 1990) 2004;40(3):436-44.
2003: Celia A Kanashiro; Andrew V Schally; Kate Groot; Patricia Armatis; Andrea L F Bernardino; Jozsef Varga
Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(26):15836-41.
2003: Zoltan Szereday; Andrew V Schally; Jozsef Varga; Celia A Kanashiro; Francine Hebert; Patricia Armatis; Kate Groot; Karoly Szepeshazi; Gabor Halmos; Rebeca Busto
Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
Cancer research 2003;63(22):7913-9.
2003: Hippokratis Kiaris; Ioulia Chatzistamou; Andrew V Schally; Gabor Halmos; Jozsef Varga; Helen Koutselini; Anastasios Kalofoutis
Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(16):9512-7.
2003: Markus Letsch; Andrew V Schally; Rebeca Busto; Ana M Bajo; Jozsef Varga
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(3):1250-5.
2003: M Olga Garcia-Fernandez; Andrew V Schally; Jozsef Varga; Kate Groot; Rebeca Busto
The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation.
Breast cancer research and treatment 2003;77(1):15-26.
2002: Magdolna Kovacs; Andrew V Schally; E-J Lee; Rebeca Busto; Patricia Armatis; Kate Groot; Jozsef Varga
Inhibitory effects of antagonistic analogs of GHRH on GH3 pituitary cells overexpressing the human GHRH receptor.
The Journal of endocrinology 2002;175(2):425-34.
2002: Ryszard Braczkowski; Andrew V Schally; Artur Plonowski; Jozsef Varga; Kate Groot; Magdalena Krupa; Patricia Armatis
Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.
Cancer 2002;95(8):1735-45.
2002: Rebeca Busto; Andrew V Schally; Ryszard Braczkowski; Artur Plonowski; Magdalena Krupa; Kate Groot; Patricia Armatis; Jozsef Varga
Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors.
Regulatory peptides 2002;108(2-3):47-53.
2002: Gabor Halmos; Andrew V Schally; Tamas Czompoly; Magdalena Krupa; Jozsef Varga; Zoltan Rekasi
Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
The Journal of clinical endocrinology and metabolism 2002;87(10):4707-14.
2002: Rebeca Busto; Andrew V Schally; Jozsef Varga; M Olga Garcia-Fernandez; Kate Groot; Patricia Armatis; Karoly Szepeshazi
The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(18):11866-71.
2002: Artur Plonowski; Andrew V Schally; Markus Letsch; Magdalena Krupa; Francine Hebert; Rebeca Busto; Kate Groot; Jozsef Varga
Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
The Prostate 2002;52(3):173-82.
2002: Artur Plonowski; Andrew V Schally; Rebeca Busto; Magdalena Krupa; Jozsef Varga; Gabor Halmos
Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers.
Peptides 2002;23(6):1127-33.
2002: Artur Plonowski; Jozsef Varga; Andrew V Schally; Magdalena Krupa; Kate Groot; Gabor Halmos
Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
International journal of cancer. Journal international du cancer 2002;98(4):624-9.
2002: Hippokratis Kiaris; Andrew V Schally; Rebeca Busto; Gabor Halmos; Spyros Artavanis-Tsakonas; Jozsef Varga
Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(1):196-200.
2001: Ioulia Chatzistamou; Andrew V Schally; Jozsef Varga; Kate Groot; Patricia Armatis; Ana M Bajo
Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Journal of cancer research and clinical oncology 2001;127(11):645-52.
2001: Ioulia Chatzistamou; Andrew V Schally; Jozsef Varga; Kate Groot; Rebeca Busto; Patricia Armatis; Gabor Halmos
Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone.
Anti-cancer drugs 2001;12(9):761-8.
2001: Andrew V Schally; Ana Maria Comaru-Schally; Attila Nagy; Magdolna Kovacs; Karoly Szepeshazi; Artur Plonowski; Jozsef Varga; Gabor Halmos
Hypothalamic hormones and cancer.
Frontiers in neuroendocrinology 2001;22(4):248-91.
2001: Karoly Szepeshazi; Andrew V Schally; Patricia Armatis; Kate Groot; Francine Hebert; A Feil; Jozsef Varga; Gabor Halmos
Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.
Endocrinology 2001;142(10):4371-8.
2001: Zoltan Rekasi; Andrew V Schally; Artur Plonowski; Tamas Czompoly; Balazs Csernus; Jozsef Varga
Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
The Prostate 2001;48(3):188-99.
2001: Zoltan Rekasi; Jozsef Varga; Andrew V Schally; Artur Plonowski; Gabor Halmos; Balazs Csernus; Patricia Armatis; Kate Groot
Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways.
Peptides 2001;22(6):879-86.
2001: Ioulia Chatzistamou; Andrew V Schally; Jozsef Varga; Kate Groot; Patricia Armatis; Rebeca Busto; Gabor Halmos
Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
The Journal of clinical endocrinology and metabolism 2001;86(5):2144-52.
2000: Hippokratis Kiaris; Andrew V Schally; Jozsef Varga
Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma.
Cancer letters 2000;161(2):149-55.
2000: Gabor Halmos; Andrew V Schally; Jozsef Varga; Artur Plonowski; Zoltan Rekasi; Tamas Czompoly
Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(19):10555-60.
2000: Artur Plonowski; Andrew V Schally; Jozsef Varga; Zoltan Rekasi; Francine Hebert; Gabor Halmos; Kate Groot
Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
The Prostate 2000;44(2):172-80.
2000: Zoltan Rekasi; Jozsef Varga; Andrew V Schally; Gabor Halmos; Patricia Armatis; Kate Groot; Tamas Czompoly
Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Endocrinology 2000;141(6):2120-8.
2000: Hippokratis Kiaris; Andrew V Schally; Jozsef Varga
Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice.
Neoplasia (New York, N.Y.) 2000;2(3):242-50.
2000: Karoly Szepeshazi; Andrew V Schally; Kate Groot; Patricia Armatis; Gabor Halmos; F Herbert; Béla Szende; Jozsef Varga; Marta Zarandi
Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.
British journal of cancer 2000;82(10):1724-31.
2000: Z Kahán; Jozsef Varga; Andrew V Schally; Z Rékási; Patricia Armatis; L Chatzistamou; T Czömpöly; Gabor Halmos
Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
Breast cancer research and treatment 2000;60(1):71-9.
2000: Zoltan Rekasi; Jozsef Varga; Andrew V Schally; Gabor Halmos; Kate Groot; Tamas Czompoly
Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(3):1218-23.
2000: Jozsef Varga; D Szabó; Miklós Hollósi
Exciton coupling in the CD spectra of chiral spiro-lambda 4-sulfanes and related sulfonium salts.
Enantiomer 2000;5(5):513-20.
1999: Hippokratis Kiaris; Andrew V Schally; Jozsef Varga; Kate Groot; Patricia Armatis
Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(26):14894-8.
1999: Jozsef Varga; Andrew V Schally; VJ Csernus; Márta Zarándi; Gabor Halmos; Kate Groot; Z Rékási
Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(2):692-7.
1998: Gábor Jancsó; Ferenc Domoki; Péter Sántha; Jozsef Varga; J Fischer; K Orosz; Botond Penke; A Becskei; Mária Dux; L Tóth
Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats.
Neuroscience letters 1998;253(2):139-41.
1998: S O'Mahony; Tibor Harkany; A A Rensink; István M Abrahám; GI de Jong; Jozsef Varga; Márta Zarándi; Botond Penke; Csaba Nyakas; Paul G M Luiten; Brian E Leonard
Beta-amyloid-induced cholinergic denervation correlates with enhanced nitric oxide synthase activity in rat cerebral cortex: reversal by NMDA receptor blockade.
Brain research bulletin 1998;45(4):405-11.
1997: Gábor Laskay; Márta Zarándi; Jozsef Varga; Krisztina Jost; A Fónagy; C Torday; L Latzkovits; Botond Penke
A putative tetrapeptide antagonist prevents beta-amyloid-induced long-term elevation of [Ca2+]i in rat astrocytes.
Biochemical and biophysical research communications 1997;235(3):479-81.
1996: Ilona Laczkó; Elemér Vass; Katalin Soós; Jozsef Varga; S Száraz; Miklós Hollósi; Botond Penke
Ca(2+)- and Al(3+)-induced conformational transitions of amyloid fragment H-Ile-Ile-Gly-Leu-Met-NH2.
Archives of biochemistry and biophysics 1996;335(2):381-7.
1994: Ilona Laczkó; S Holly; Zoltan Kónya; Katalin Soós; Jozsef Varga; Miklós Hollósi; Botond Penke
Conformational mapping of amyloid peptides from the putative neurotoxic 25-35 region.
Biochemical and biophysical research communications 1994;205(1):120-6.
1993: A Bidzseranova; Jozsef Varga; Gyula Telegdy
The effects of brain natriuretic peptide-32 on electroconvulsive shock-induced amenesia in rats. The role of neurotransmitters.
European journal of pharmacology 1993;232(2-3):305-8.
1993: A M Mazarati; E Halászi; Gyula Telegdy; G Tóth; Jozsef Varga
ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats.
Life sciences 1993;52(3):PL19-24.
1992: A Bidzseranova; J Gueron; G Tóth; Jozsef Varga; Gyula Telegdy
Structure-activity studies on the effects of atrial natriuretic peptide, brain natriuretic peptide and their analogs on fear-motivated learning behavior in rats.
Neuropeptides 1992;23(2):61-5.
1992: A Bidzseranova; J Gueron; Jozsef Varga; Gyula Telegdy
Effects of brain natriuretic peptide-32 on the extinction of active avoidance behavior in rats. Transmitter-mediated action.
Physiology & behavior 1992;52(2):227-9.
1992: A Bidzseranova; J Gueron; G Tóth; Botond Penke; Jozsef Varga; Gyula Telegdy
Behavioral effects of atrial and brain natriuretic peptides in rats.
Neuroreport 1992;3(3):283-5.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.